About Max Stanyard

Max Stanyard sits within RSM's Industry Eminence Programme, bringing dedicated sector expertise to help middle market healthcare and life sciences businesses understand the trends and opportunities defining their industry. Drawing on a deep understanding of the forces reshaping the sector, Max translates complex dynamics into practical, forward-looking intelligence for business leaders.

Max is also an Associate Director in RSM's Innovation and Capital Tax Reliefs team, advising businesses on R&D tax reliefs and other innovation incentives, helping life sciences companies – from early-stage biotechs to established pharmaceutical and medtech firms – unlock the capital they need to grow and innovate.

Max is ACA qualified, having trained in RSM's audit practice where he gained extensive experience working with large listed entities across a range of sectors. Prior to a career in professional services, Max studied Pharmacology at degree level – a foundation that provides a genuine scientific understanding of the life sciences industry and its unique complexities. This combination of technical financial expertise and first-hand knowledge of the science underpinning drug discovery, development and commercialisation allows Max to engage with life sciences clients with both commercial and scientific credibility.

RSM timeline:

• 2025: selected for the RSM Industry Eminence Programme as the healthcare and life sciences senior analyst
• 2024: promoted to Associate Director in the Innovation & Capital Tax Reliefs team
• 2021: transferred into the ICTR team post qualification
• 2016: joined RSM as a graduate